ACUMEN PHARMACEUTICALS INC. - COMMON STOCK

Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights

13 أغسطس 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024

06 أغسطس 2024 15:00:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease

29 يوليو 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

28 يوليو 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

11 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

14 مايو 2024 06:00:01 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 مايو 2024 15:00:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

08 مايو 2024 16:47:25 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

08 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

07 مايو 2024 15:00:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

16 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease

04 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

26 مارس 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting

21 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

19 مارس 2024 15:00:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

12 مارس 2024 15:00:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

08 مارس 2024 07:50:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

21 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

01 فبراير 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

04 يناير 2024 15:15:20 بحسب Nasdaq GlobeNewswire